Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate for the prevention of complications post bone marrow transplantations; treatment of patients that do not respond to steroid treatment upon occurrence of graft vs host disease post bone marrow transplantations; and prevention of cytokine storms, organ damage, and multiple organ failure in sepsis patients. The company also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor T-Cell therapy and therapies targeting T-Cell receptor therapy. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone972-2670-8072
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees31
Next Earnings Date5/5/2020 (Estimated)
OptionableNot Optionable
Enlivex Therapeutics (NASDAQ:ENLV) Frequently Asked Questions
What is Enlivex Therapeutics' stock symbol?
Enlivex Therapeutics trades on the NASDAQ under the ticker symbol "ENLV."
When is Enlivex Therapeutics' next earnings date?
What price target have analysts set for ENLV?
1 brokers have issued 1 year target prices for Enlivex Therapeutics' stock. Their forecasts range from $20.00 to $20.00. On average, they anticipate Enlivex Therapeutics' stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 138.1% from the stock's current price. View Analyst Price Targets for Enlivex Therapeutics.
What is the consensus analysts' recommendation for Enlivex Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enlivex Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Enlivex Therapeutics.
Has Enlivex Therapeutics been receiving favorable news coverage?
News coverage about ENLV stock has been trending somewhat positive recently, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Enlivex Therapeutics earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Enlivex Therapeutics.
Are investors shorting Enlivex Therapeutics?
Enlivex Therapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 5,500 shares, an increase of 10.0% from the January 15th total of 5,000 shares. Based on an average daily volume of 36,600 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.1% of the company's shares are short sold. View Enlivex Therapeutics' Current Options Chain.
Who are some of Enlivex Therapeutics' key competitors?
Some companies that are related to Enlivex Therapeutics include Rigel Pharmaceuticals (RIGL), Recro Pharma (REPH), Mirum Pharmaceuticals (MIRM), Verrica Pharmaceuticals (VRCA), Lannett (LCI), INDIVIOR PLC/S (INVVY), Corbus Pharmaceuticals (CRBP), Avadel Pharmaceuticals (AVDL), Spectrum Pharmaceuticals (SPPI), Stemline Therapeutics (STML), Minerva Neurosciences (NERV), CytomX Therapeutics (CTMX), Evolus (EOLS), Concert Pharmaceuticals (CNCE) and AMAG Pharmaceuticals (AMAG).
What other stocks do shareholders of Enlivex Therapeutics own?
Who are Enlivex Therapeutics' key executives?
Enlivex Therapeutics' management team includes the folowing people:
- Mr. Shai Novik, Exec. Chairman (Age 54)
- Prof. Dror Mevorach M.D., Chief Scientific and Medical Officer & Interim CEO (Age 64)
- Dr. Oren Hershkovitz, Chief Exec. Officer
- Ms. Shachar Shlosberger, Chief Financial Officer (Age 43)
- Odelia Ben-Shitrit, Head of Clinical Operations
Who are Enlivex Therapeutics' major shareholders?
Enlivex Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (0.37%) and Renaissance Technologies LLC (0.37%).
Which institutional investors are buying Enlivex Therapeutics stock?
ENLV stock was bought by a variety of institutional investors in the last quarter, including ARK Investment Management LLC and Renaissance Technologies LLC.
How do I buy shares of Enlivex Therapeutics?
Shares of ENLV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Enlivex Therapeutics' stock price today?
One share of ENLV stock can currently be purchased for approximately $8.40.
How big of a company is Enlivex Therapeutics?
Enlivex Therapeutics has a market capitalization of $86.77 million. The company earns $-4,240,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Enlivex Therapeutics employs 31 workers across the globe.View Additional Information About Enlivex Therapeutics.
What is Enlivex Therapeutics' official website?
How can I contact Enlivex Therapeutics?
Enlivex Therapeutics' mailing address is 14 Einstein Street, Nes Ziona L3, 7403618. The company can be reached via phone at 972-2670-8072 or via email at [email protected]
MarketBeat Community Rating for Enlivex Therapeutics (NASDAQ ENLV)
MarketBeat's community ratings are surveys of what our community members think about Enlivex Therapeutics and other stocks. Vote "Outperform" if you believe ENLV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENLV will underperform the S&P 500 over the long term. You may vote once every thirty days.
